Helix BioPharma Announces the Appointment of Kazimierz Roszkowski-Sliz, M.D., Ph.D.,...

Helix BioPharma Announces the Appointment of Kazimierz Roszkowski-Sliz, M.D.,
Ph.D., to its Board of Directors

AURORA, Ontario, Aug. 17 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TSX,
FSE: HBP / OTCQX: HXBPF) today announced the appointment of Kazimierz
Roszkowski-Sliz, M.D., Ph.D., to its board of directors. Professor
Roszkowski-Sliz is replacing Professor Slawomir Majewski, who has stepped down
from the board to assume the advisory role of European medical director for
Helix.

Professor Roszkowski-Sliz is an expert in the field of lung disease and lung
cancers, and is a director at the National Tuberculosis and Lung Diseases
Research Institute in Warsaw where he is also head of the clinical department.
In addition, Professor Roszkowski-Sliz consults on lung diseases issues for
the Polish Ministry of Health. He received his M.D. from the Medical Academy
in Warsaw and his Ph.D. from the Postgraduate Medical Center in Warsaw. He is
an accomplished researcher with over 230 published papers.

"Professor Roszkowski-Sliz is an excellent addition to our board of
directors," said Donald H. Segal, Ph.D., chairman and CEO of Helix BioPharma.
"His expertise in lung disease, especially lung cancer, will be invaluable to
Helix as we continue to drive our L-DOS47 non-small cell lung cancer program
towards clinical development. We also want to thank Professor Majewski for
his service on the board. We are fortunate that he will continue to provide
us with guidance on our European clinical development activities."

"Helix's novel approach to the challenging problem of lung cancer is a very
interesting and innovative one," said Professor Roszkowski-Sliz. "I am
looking forward to working with the rest of the board and the management team
to help guide L-DOS47 into and through the clinical development process."

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field
of cancer therapy. The Company is actively developing innovative products for
the prevention and treatment of cancer based on its proprietary technologies.
Helix's product development initiatives include its Topical Interferon
Alpha-2b and its novel L-DOS47 new drug candidate. Helix is listed on the TSX
and FSE under the symbol "HBP" and on the OTCQX International Market under the
symbol "HXBPF".

For further information contact:
Investor & Media Relations
Ian Stone
Russo Partners LLC
Tel: (619) 814-3510
Fax: (619) 955-5318
Email: ian.stone@russopartnersllc.com

Robert Flamm, Ph.D.
Russo Partners LLC
Tel: (212) 845-4226
Email: robert.flamm@russopartnersllc.com
www.russopartnersllc.com

Editor's Note: Photograph is available on request

This News Release contains certain forward-looking statements and information
regarding the Company's product development initiatives and in particular, its
L-DOS47 new drug candidate, which statements and information can be identified
by the use of forward-looking terminology such as "continue", "drive",
"towards", "forward", "guide", "into and through the clinical development
process", "developing", or variations thereon, or comparable terminology
referring to future events or results. Forward looking statements and
information are statements and information about the future and are inherently
uncertain. Helix's actual results could differ materially from those
anticipated in these forward-looking statements and information as a result of
numerous risks and uncertainties including without limitation, the Company's
need for additional capital which, if not obtained in a timely manner or at
all, will have a material adverse impact on the Company, its research and
development programs and ultimately, its ability to continue; the impact of
the global economic downturn and credit crisis which have negatively affected
the availability of additional capital, particularly for development stage
biotechnology companies such as Helix; uncertainty whether L-DOS47 or Topical
Interferon Alpha-2b will be successfully developed and commercialized as a
drug or at all; the need for additional pre-clinical and clinical research and
development, which may not be successful or completed in a timely manner;
manufacturing and upscaling risks, including the possibility that further
challenges may arise in connection with the manufacture of clinical batches of
L-DOS47 or Topical Interferon Alpha-2b which could further delay or otherwise
negatively affect the Company's planned development programs; the risk of
obtaining negative findings or factors that may become apparent during the
course of research or development, which may result in the discontinuation or
delay of the research or development projects; the need for future clinical
trials, the occurrence and success of which cannot be assured; product
liability and insurance risks; the risk of technical obsolescence; the need
for further regulatory approvals, which may not be obtained in a timely matter
or at all; intellectual property risks; Helix's dependence on numerous third
parties, including without limitation, contract research organizations,
contract manufacturing organizations, clinical trial consultants,
collaborative research consultants, regulatory affairs advisors, and others,
whose performance and interdependence can critically affect the Company's
performance and the achievement of its milestones; Helix's dependence on its
licensor of the L-DOS47 antibody, and on the antibody license granted to
Helix, for the continued development of L-DOS47; the need to secure new
strategic relationships, which is not assured, to commercialize L-DOS47 and
any other drug candidates which may arise out of DOS47; the risk that the
Company's license optionee for Topical Interferon Alpha-2b may not continue to
provide the Company with interferon alpha-2b or exercise its option, which
would have a negative effect on the further development of the drug candidate
and on the Company; the risk of unanticipated expenses or unanticipated
reductions in revenue, or both; the effect of competition; uncertainty of the
size and existence of a market opportunity for Helix's products; and the risk
of changes in business strategy or development plans. Such risks and
uncertainties, and others affecting the Company which could cause actual
results to vary materially from current results or those anticipated in
forward-looking statements and information, are more fully described in the
Company's latest Annual Information Form, MD&A and other reports filed with
the Canadian Securities Regulatory Authorities from time to time at
www.sedar.com, and in the Company's Form 20-F and other reports filed with the
U.S. S.E.C. from time to time (see www.sec.gov/edgar.shtml). Forward-looking
statements and information are based on the beliefs, assumptions, opinions and
expectations of Helix's management at the time they are made, and Helix does
not assume any obligation to update any forward-looking statement or
information should those beliefs, assumptions, opinions or expectations
change, except as required by law.

SOURCE Helix BioPharma Corp.

Investor & Media Relations, Ian Stone, Russo Partners LLC, +1-619-814-3510,
Fax: +1-619-955-5318, ian.stone@russopartnersllc.com; or Robert Flamm, Ph.D.,
Russo Partners LLC, +1-212-845-4226, robert.flamm@russopartnersllc.com